Differences in quality of life, Anxiety and depression in patients with paroxysmal atrial fibrillation and common forms of atrioventricular reentry supraventricular tachycardias

Indian Pacing and Electrophysiology Journal

Volumn 14, Issue 5, 2014, Pages 250-257

  Lioni, Louiza ^a   Vlachos, Konstantinos ^a   Letsas, Konstantinos P ^a   Efremidis, Michael ^a   Karlis, Dimitrios ^a   Asvestas, Dimitrios ^a   Kareliotis, Vasilios ^a   Xydonas, Sotirios ^a   Dimopoulos, Nikolaos ^b   Korantzopoulos, Panagiotis ^c   Trikas, Athanasios ^d   Sideris, Antonios ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b Dromokaiteio Psychiatric Hospital of Attica   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d KAT HOSPITAL   (Greece)

Author keywords

Anxiety; Atrial fibrillation; Depression; Quality of life; Supraventricular tachycardias

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ANXIETY; ARTICLE; ATRIOVENTRICULAR REENTRY SUPRAVENTRICULAR TACHYCARDIA; BECK DEPRESSION INVENTORY; CATHETER ABLATION; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; EMOTION; FEMALE; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL STRESS; PHYSICAL ACTIVITY; QUALITY OF LIFE; REENTRY ARRHYTHMIA; SHORT FORM 36; STATE TRAIT ANXIETY INVENTORY;

EID: 84907515830     PISSN: None     EISSN: 09726292     Source Type: Journal    
DOI: 10.1016/S0972-6292(16)30796-3     Document Type: Article

References (34)

1. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36:1303-9.
2. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest. 2007;132:1259-64.
3. Eaker ED, Sullivan LM, Kelly-Hayes M, D'Agostino RB Sr, Benjamin EJ. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med. 2005;67:692-6.
4. Fichtner S, Deisenhofer I, Kindsmuller S, et al. Prospective assessment of short- and longterm quality of life after ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2012;23:121-7.
5. Walfridsson U, Stromberg A, Janzon M, Walfridsson H. Wolff-Parkinson-White syndrome and atrioventricular nodal re-entry tachycardia in a Swedish population: consequences on healthrelated quality of life. Pacing Clin Electrophysiol 2009; 32:1299-306.
6. Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997;79:145-9.
7. Kitzlerova E, Anders M, Kautzner J, Dohnalova A. Evaluation of psychopathology in patients with paroxysmal supraventricular tachycardia. Exp Clin Cardiol. 2007;12:42-5.
8. Meissner A, Stifoudi I, Weismuller P, et al. Sustained high quality of life in a 5- year long term follow-up after successful ablation for supra-ventricular tachycardia. results from a large retrospective patient cohort. Int J Med Sci. 2009;6:28-36.
9. Lessmeier TJ, Gamperling D, Johnson-Liddon V, et al. Unrecognized paroxysmal supraventricular tachycardia. Potential for misdiagnosis as panic disorder. Arch Intern Med 1997;157:537-543.
10. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
11. Efremidis M, Letsas KP, Lioni L, et al. The impact of vagotonic, adrenergic, and random type of paroxysmal atrial fibrillation on left atrial ablation outcomes. Int J Cardiol. 2013 9;168:4015-8.
12. Knight BP, Ebinger M, Oral H, et al. Diagnostic value of tachycardia features and pacing maneuvers during paroxysmal supraventricular tachycardia. J Am Coll Cardiol 2000; 36: 574-82.
13. Letsas KP, Weber R, Siklody CH, et al. Electrocardiographic differentiation of common type atrioventricular nodal reentrant tachycardia from atrioventricular reciprocating tachycardia via a concealed accessory pathway. Acta Cardiol. 2010;65:171-6.
14. Efremidis M, Sideris A, Letsas KP, et al. Potential-guided versus anatomic-guided approach for slow pathway ablation of the common type atrioventricular nodal reentry tachycardia: a randomized study. Acta Cardiol. 2009;64:477-83.
15. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
16. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
17. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. California: Consulting Psychologists Press, 1983.
18. Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med. 200;63:221-30.
19. Fountoulakis KN, Papadopoulou M, Kleanthous S, et al. Reliability and psychometric properties of the Greek translation of the State-Trait Anxiety Inventory form Y: preliminary data. Ann Gen Psychiatry. 2006;5:2.
20. Pelle AJ, Denollet J, Zwisler AD, Pedersen SS. Overlap and distinctiveness of psychological risk factors in patients with ischemic heart disease and chronic heart failure: are we there yet? J Affect Disord. 2009;113:150-6.
21. Blumenthal JA, Sherwood A, Babyak MA, et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005;293:1626-34.
22. Fountoulakis KN, Iacovides A, Kleanthous S, et al. The Greek translation of the symptoms rating scale for depression and anxiety: preliminary results of the validation study. BMC Psychiatry. 2003;3:21.
23. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.
24. McCabe PJ. Psychological distress in patients diagnosed with atrial fibrillation: the state of the science. J Cardiovasc Nurs. 2010;25:40-51.
25. O'Donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun 2010;24:1074-1077.
26. Pitsavos C, Panagiotakos DB, Papageorgiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis 2006;185:320-326.
27. Maes M, Song C, Lin A, et al. The effects of psychological stress on humans: increased production of proinflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998;10:313-318.
28. Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci USA 2012;109:5995-5999.
29. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-1184.
30. Letsas KP, Weber R, Burkle G, et al. Preablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 2009;11:158-163.
31. Miki K, Yoshimoto M. Sympathetic nerve activity during sleep, exercise, and mental stress. Auton Neurosci 2013;174:15-20.
32. Hughes JW, Watkins L, Blumenthal JA, Kuhn C, Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res 2004;57:353-358.
33. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm 2007;4:S61-S64.
34. Deftereos S, Giannopoulos G, Kossyvakis C, et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013;112:684-687.